Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy
- 44 Downloads
Adjuvant endocrine therapy remains the most important systemic intervention recommended to women with breast cancer whose tumors contain the estrogen receptor (ER) or progesterone receptor. Results from over a dozen prospective clinical trials have consistently demonstrated that the incorporation of the third generation aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, in the adjuvant setting, instead of or in sequence with tamoxifen, were superior to 5 years of single agent tamoxifen in reducing breast cancer-related relapse or death . In addition to a small superiority in efficacy, AIs are associated with a slightly different safety profile compared to tamoxifen. Biomarkers that could help predict efficacy and safety to specific endocrine interventions or even to specific agents are greatly needed and could be used to personalize various endocrine manipulations for individual women. Predictive biomarkers may be tumor or host specific, and may be...
KeywordsTamoxifen Breast Cancer Risk Letrozole Breast Density Benign Breast Disease
Conflict of interest
Dr. Stearns received investigator-initiated research grants from Novartis and Pfizer, and honoraria from Astra Zeneca.
- 1.Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629CrossRefPubMedGoogle Scholar
- 4.Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162(9):826–834CrossRefPubMedGoogle Scholar
- 8.Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE (2009) A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0662-0 PubMedGoogle Scholar
- 11.McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol 27(36):6135–6143CrossRefPubMedGoogle Scholar